Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.011
Neutral
RSI(14)
28.875
Sell
STOCH(KDJ)(9,3,3)
12.130
Oversold
ATR(14)
0.076
Low Volatility
CCI(14)
-131.087
Sell
Williams %R
93.515
Oversold
TRIX(12,20)
-1.122
Sell
StochRSI(14)
19.898
Sell
Search
Tempest Therapeutics Inc
TPSTAdd to Watchlist
0.856USD
-0.007-0.86%
Close 07-31 16:00（ET）Quotes delayed by 15 min
12.28MMarket Cap
0.03P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.86%
5 Days
-7.52%
1 Month
-22.86%
6 Months
-68.52%
Year to Date
-70.16%
1 Year
-88.16%
Key Figures
0.883Open
0.888High
69.51KVolume
0.03P/E TTM
LossP/E Dynamic
--Dividend TTM
0.48%Turnover Ratio
0.864Prev. Close
0.853Low
42.39KTurnover
LossP/E Static
14.94P/B
0.00%Div Yield TTM
-200.87%ROA
12.23052wk High
0.47Volume Ratio
-41.84MNet Profit
14.34MShares
32.2064EPS TTM
-1.78Beta
-721.00%ROE
1.50052wk Low
4.08%Amplitude
--Gross Margin
12.28MMarket Cap
-3.56Reward/Risk
5.84%Risk Rate
TradingKey Stock Score of Tempest Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Tempest Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 117 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tempest Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Tempest Therapeutics Inc Highlights
StrengthsRisks
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Overvalued
The company’s latest PE is 0.03, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.51M shares, increasing 44.27% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
11.000
Target Price
+1132.63%
Upside Space
Tempest Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Buy
Current Rating
11.000
Target Price
+1132.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Tempest Therapeutics Inc
TPST
1
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.884
Sell
MA10
0.918
Sell
MA20
0.958
Sell
MA50
1.192
Sell
MA100
1.560
Sell
MA200
3.136
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Tempest Therapeutics Inc Info
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Ticker SymbolTPST
CompanyTempest Therapeutics Inc
CEO
Websitehttps://www.tempesttx.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Tempest Therapeutics Inc (TPST)?
The current price of Tempest Therapeutics Inc (TPST) is 0.86.
What is the symbol of Tempest Therapeutics Inc?
The ticker symbol of Tempest Therapeutics Inc is TPST.
What is the 52-week high of Tempest Therapeutics Inc?
The 52-week high of Tempest Therapeutics Inc is 12.23.
What is the 52-week low of Tempest Therapeutics Inc?
The 52-week low of Tempest Therapeutics Inc is 1.50.
What is the market capitalization of Tempest Therapeutics Inc?
The market capitalization of Tempest Therapeutics Inc is 12.28M.
Is Tempest Therapeutics Inc (TPST) currently rated as Buy, Hold, or Sell?
According to analysts, Tempest Therapeutics Inc (TPST) has an overall rating of Buy, with a price target of 11.00.
What is the Earnings Per Share (EPS TTM) of Tempest Therapeutics Inc (TPST)?
The Earnings Per Share (EPS TTM) of Tempest Therapeutics Inc (TPST) is -6.33.